A scoping review of virtual reality technology utilization in patients with colorectal cancer Authors: Yiyun Huang, Zhoumin Shen, Juan Tan, Yin Hu, Miyao Wu, Pengpeng Gao, Feilan Jiang, Hongdan Jiang Published: 2026 ABSTRACT BackgroundVirtual reality (VR) technology has shown promise in supporting colorectal cancer (CRC) patients throughout their care journey; however, the evidence concerning its specific applications, intervention characteristics, and clinical outcomes remains scattered. This scoping review aims to systematically map the application domains, intervention features, implementation effects, and current challenges of VR in CRC patients, thereby providing an evidence base for nursing practice and the development of personalised rehabilitation programmes.MethodsFollowing the Joanna Briggs Institute (JBI) methodological framework for scoping reviews, we systematically searched eight databases (CNKI, Wanfang Data, VIP, Web of Science, Embase, PubMed, CINAHL, and Cochrane Library) from their inception to January 26, 2026. Original studies that applied VR technology to patients with colorectal cancer were included. Two independent reviewers performed study selection, data extraction, and analysis.ResultsSeven studies published between 2021 and 2025, involving a total of 388 participants, were included: 4 randomised controlled trials, 2 pilot studies, and 1 mixed-methods study. VR applications covered preoperative education, postoperative rehabilitation, chemotherapy management, and palliative support. Intervention types included immersive relaxation/meditation training, VR health education, VR rehabilitation training (interactive exergaming), and multisensory VR simulation. Session durations ranged from 7 to 30 minutes, with frequencies from a single session to twice daily; most intervention periods were single-session or aligned with hospitalisation/chemotherapy cycles. Six studies reported that VR reduced anxiety or improved emotional state, four noted improvements in physiological parameters, and two reported enhanced comprehension of surgical procedures. No serious adverse events were documented; only three mild cases of motion sickness were reported among the 388 participants (0.77%), indicating a low overall incidence of VR-related discomfort.ConclusionThe findings suggest that VR interventions may offer tentative indications of benefit in alleviating anxiety and improving mood among CRC patients. The available data also provide preliminary safety evidence, with only two mild motion sickness cases reported. However, given the limited and highly heterogeneous evidence base (n=7 studies; N=388 participants), these observations must be construed as strictly hypothesis‑generating rather than practice‑changing. Definitive conclusions regarding clinical efficacy and safety necessitate validation through large‑scale, adequately powered randomised controlled trials with standardised protocols. Introduction Colorectal cancer (CRC) remains a major global health challenge, with nearly two million newly diagnosed cases in 2022 and the disease ranking as the second leading cause of cancer‑related mortality worldwide [1–2]. The situation in China is particularly concerning. According to the recent research [3], the country recorded approximately 658,321 new CRC cases and 275,129 related deaths in 2021, with both incidence and mortality rates having risen steadily over the past three decades. This escalating trend—driven by rapid urbanisation, shifting dietary patterns, sedentary lifestyles, and accelerated population ageing—has rendered CRC one of the most prominent malignancies threatening public health in China [4–5]. In response to these pressing challenges, the nation‘s latest health strategy has explicitly prioritised high-quality rehabilitation nursing and advocated for holistic, full-cycle health management for cancer patients, while simultaneously promoting the integration of digital medical technologies—including virtual reality—into routine clinical practice [6]. Against this policy backdrop, there is an urgent imperative to explore innovative, technology-assisted interventions that are not only clinically effective but also culturally appropriate and economically viable within the Chinese healthcare context. Despite substantial improvements in survival due to surgery and chemotherapy, CRC survivors frequently suffer from a range of debilitating symptoms, including pain, fatigue, anxiety, depression, chemotherapy‑related adverse effects and a diminished quality of life [7–9]. Conventional rehabilitation strategies—for instance, early mobilisation guidance, breathing exercises and psychological support—can alleviate some of these symptoms to a certain extent. However, their repetitive nature, lack of interactive engagement, and absence of real‑time feedback often result in poor patient motivation and low long‑term adherence [10–12], thereby limiting their overall effectiveness. Virtual reality (VR) represents a promising therapeutic modality for patients with colorectal cancer (CRC) [13]. The therapeutic potential of VR in this population can be conceptualised through three theoretical frameworks. First, attentional deployment (distraction theory) posits that immersive VR environments effectively divert patients’ focus away from salient distressing stimuli—such as procedural pain, anticipatory nausea, or preoperative anxiety—thereby attenuating the cognitive and emotional burden of these aversive experiences [14–15]. Second, cognitive reappraisal extends this passive diversion into active meaning-making; through three-dimensional anatomical visualisations, VR enables patients to reframe threatening clinical scenarios (e.g., surgical invasion or stoma creation), which may reduce uncertainty-related distress and reinforces a subjective sense of preparedness and control [16–17]. Third, behavioural activation, particularly via interactive exergaming, promotes physical mobilisation and may trigger reward-related neurobiological pathways, directly counteracting the profound fatigue and social withdrawal that frequently complicate postoperative recovery and prolonged chemotherapy [18–19]. Critically, these mechanisms are not siloed. Viewed through the biopsychosocial model, this interconnectedness underscores that VR’s efficacy cannot be reduced to mere psychological distraction; rather, it simultaneously modulates physical symptoms (fatigue, pain), psychological states (anxiety, self-efficacy), and social engagement (reducing withdrawal) [20–21]. A thorough appreciation of these underpinnings is essential for tailoring theory-driven, stage-specific VR strategies across the CRC care continuum. By integrating visual, auditory, and somatosensory stimuli, VR creates immersive, interactive, and individually customisable environments that can enhance patient engagement and sustain rehabilitation motivation. VR has already shown beneficial effects in orthopaedic and neurological rehabilitation [22–23]. Importantly, CRC patients face unique challenges—such as prolonged chemotherapy cycles, post‑operative bowel dysfunction, stoma care, and chemotherapy‑induced nausea and fatigue—that may be particularly amenable to VR interventions. For example, immersive distraction can reduce anticipatory anxiety and chemotherapy‑related distress, while interactive exergaming can promote physical activity in a home‑based setting. Consequently, a growing number of studies have started to explore the use of VR for perioperative management, symptom control, and rehabilitation training in CRC patients [24–25]. Nevertheless, evidence regarding the application of VR in CRC care remains notably fragmented. Although several systematic reviews have synthesised findings from cancer populations [26–27] or from general abdominal surgery [24], no scoping review to date has specifically targeted CRC patients across the entire care trajectory—from pre-operative preparation through to palliative support. Meanwhile, emerging primary studies have reported encouraging results, suggesting that VR interventions may alleviate stress and anxiety during chemotherapy and improve patient satisfaction during invasive diagnostic procedures such as colonoscopy [28–29]. However, these promising but isolated findings have yet to be systematically mapped or consolidated within the specific CRC context. Consequently, a conspicuous evidence gap persists regarding the precise application domains, core intervention characteristics (e.g., content, device types, and dosing parameters), standardised outcome measures, and long-term effectiveness of VR interventions tailored to this population. This gap not only undermines the translation of VR into evidence-based nursing practice but also impedes the development of personalised, culturally responsive rehabilitation programmes for CRC survivors. Therefore, this scoping review aims to systematically identify and synthesise available literature on VR technology applied to CRC patients. Specifically, we map the application domains (e.g., preoperative education, postoperative rehabilitation, chemotherapy management, palliative support), describe intervention characteristics (device types, content, dosage parameters), summarise implementation effects (physiological, psychological, behavioural, and quality‑of‑life outcomes), and identify existing challenges. By doing so, we provide an evidence‑based foundation for nurses to design and implement personalised VR‑assisted rehabilitation programmes, and highlight priorities for future large‑scale, culturally tailored studies—particularly in the Chinese healthcare context. Methods Study design This review adopted the methodological framework proposed by the Joanna Briggs Institute (JBI) for scoping review [30]. A scoping review approach was selected because it enables the systematic mapping of existing literature, identification of key concepts, and examination of the range of evidence concerning emerging and heterogeneous interventions, such as VR technology. We have registered the protocol on the Open Science Framework (OSF) (registration DOI: https://doi.org/10.17605/OSF.IO/JFDWN). The registered protocol details the research questions, search strategy, eligibility criteria, and data extraction procedures, ensuring full transparency of our methodological approach. Clarifying the research questions Based on a preliminary search of the relevant literature, the following specific research questions were formulated to guide the review process: ① What are the main application stages (e.g., preoperative, intraoperative, postoperative) and specific domains of VR technology in patients with colorectal cancer? ② What are the characteristics of VR interventions, including content, device types, interaction modalities, and dosage (frequency, duration, and intervention period), across different application domains? ③ What effects do VR interventions have on physiological parameters, psychological states, behaviour and knowledge, and quality of life in colorectal cancer patients? ④ What are the current limitations of the existing evidence and potential directions for future research? Search strategy A systematic and comprehensive literature search was conducted across eight electronic databases: China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Chinese Science and Technology Periodical Database, Web of Science, Embase, PubMed, CINAHL, and the Cochrane Library. The search period extended from the inception of each database to January 26, 2026. Both subject headings (MeSH terms where applicable) and free-text words were employed, combined with Boolean operators (AND, OR). The detailed search strategies were tailored to each database. An example of the PubMed search strategy is presented below: #1: “Colorectal Neoplasm“[Mesh] OR “Colorectal Neoplasm“[Title/Abstract] OR “Adenomatous Polyposis Coli“[Title/Abstract] OR “Colonic Neoplasms“[Title/Abstract] OR “Colorectal Neoplasms, Hereditary Nonpolyposis“[Title/Abstract] OR “Rectal Neoplasm“[Title/Abstract] OR “Anus Neoplasm“[Title/Abstract] OR “Colorectal Tumor“[Title/Abstract] OR “Colorectal Cancer“[Title/Abstract] OR “Colorectal Carcinoma“[Title/Abstract]. #2: “Virtual Reality“[Mesh] OR “Educational Virtual Realit“[Title/Abstract] OR “Virtual Realit“[Title/Abstract] OR “Avatar“[Title/Abstract] OR “Haptic Technology“[Title/Abstract] OR “Augmented Realit“[Title/Abstract] OR “Mixed Realit“[Title/Abstract] OR “Digital Visualization“[Title/Abstract]. #3: #1 AND #2. Although AR- and MR-related terms were intentionally incorporated into the search strategy to enhance sensitivity—given that preliminary scoping searches revealed misclassification of some VR-related studies under these tags—records captured by these terms were still subjected to the full screening process. Studies exclusively employing AR or MR technologies, without any VR component, were excluded only at the full-text review stage, in accordance with the eligibility criteria. Eligibility criteria Guided by the JBI framework, the eligibility criteria were structured according to the PCC mnemonic: ① Population: patients with a pathologically confirmed diagnosis of colorectal cancer, irrespective of disease stage or treatment phase; ② Concept: any application of VR technology, encompassing immersive, non-immersive, and interactive rehabilitation gaming; ③ Context: all healthcare settings where CRC patients receive care, including preoperative clinics, post-surgical wards, chemotherapy units, and palliative care environments. Studies focusing exclusively on augmented reality (AR) or mixed reality (MR) were excluded. Studies were excluded if they: ① were not written in Chinese or English; ② had unavailable full text; ③ were conference abstracts, reviews, study protocols, or commentary articles; ④ were duplicate publications (only the most complete version was retained). We recognise that the exclusion of conference abstracts, reviews, and protocols—while methodologically necessary to ensure sufficient detail for data extraction—may carry a potential risk of publication bias. This limitation is further addressed in the Discussion section. Study selection and data extraction All retrieved records were imported into EndNote X9 software for duplicate removal. Two researchers, who had received formal training in evidence-based methodology, independently conducted the study selection process. Initially, titles and abstracts were screened against the eligibility criteria. Subsequently, the full texts of potentially relevant articles were retrieved and assessed in detail. Any disagreements between the two reviewers were resolved through discussion or consultation with a third reviewer. A standardised data extraction sheet was developed and piloted by the research team. Extracted data encompassed: ① bibliometric details (author, year, country); ② study design and sample characteristics; ③ VR intervention specifics, including device types, software content, delivery mode, frequency, duration, and total intervention period; ④ comparator conditions; ⑤ outcome measures and principal findings. Methodological quality appraisal In accordance with the Joanna Briggs Institute (JBI) methodological guidance for scoping reviews, a formal critical appraisal or risk-of-bias assessment of the included studies was not performed, as the primary objective of this review is to map the available evidence rather than to evaluate methodological quality or generate pooled effect estimates. Data analysis and presentation The extracted data were analysed and synthesised using descriptive statistics and thematic analysis. Quantitative data (e.g., intervention duration, frequency) were summarised using frequencies and ranges, while narrative synthesis was employed to categorise and describe intervention types, application domains, outcome measures, and effects. Key findings are presented in tabular format (Table 1) and accompanied by a narrative summary organised according to the research questions [31–37]. The heterogeneity of the included studies precluded meta-analysis; thus, a narrative integration of results is provided. Table 1Basic characteristics of included studiesStudy (Author, Year, Country)Design & Sample(n)Population(CRC Stage / Phase)VR Intervention vs. ComparatorDosage Parameters(Duration/Frequency/Period)Key Quantitative Outcomes(Change from baseline, Between-group differences)Safety & FeasibilityTurrado et al.[31]2021SpainRCT; n = 126Perioperative CRC surgeryVR: Customized 16-min 34-sec immersive perioperative journey (unlimited repeats)Comparator: Usual perioperative careSingle session preoperatively; Unlimited repeat viewing allowedAnxiety (STAI): Significantly lower post-operative scores in VR group (P < 0.001). Anxiety (HAD-A): Significantly lower in VR group (P < 0.001). Depression (HAD-D): No significant difference reported.Safety: None reported.Feasibility: 100% adherence; patients asked more proactive questions.Schrempf et al.[32]2022GermanyRCT; n = 54Perioperative CRC / liver metastasesVR: Oculus Go + TRIPP meditation (nature scenes)Comparator 1: Music listeningComparator 2: Usual careMorning: 7–8 min; Evening: 10 min; Twice daily throughout hospital stayPhysiological: ↓ HR (Mean diff:−1.3 bpm, 95% CI−2.2 to−0.4, P = 0.012); ↓ RR (−0.6 brpm, 95% CI−1.1 to−0.2, P = 0.012). Psychological: ↑ Overall mood (MD + 0.79, 95% CI 0.38–1.20, P = 0.001). QoL (EORTC): No significant inter-group differences.Safety: None reported.Feasibility: 81.6% adherence rate.Shepherd et al.[33]2022AustraliaPilot (Two-arm); n = 9Preoperative CRC surgeryVR: 3D reconstructed CT model via headsetComparator: Standard 2D CT image discussionSingle session (Preoperative)Subjective understanding (aggregate score): VR 45 ± 2.19 vs. Control 43 ± 2.82 (4.44% higher); Objective location accuracy: VR 100% vs. Control 80%.Safety: None reported.Feasibility: 100% adherence; satisfaction > 90%.Kelleher et al.[34]2022USAPilot (Single-arm); n = 20Advanced stage CRC (Palliative)(Palliative)VR: 30-min virtual ocean environment (VR Blue - coral reefs)Comparator: None (pre-post design)Single 30-minute sessionAnxiety (VAS): ↓ from 19.55 to 6.80 (P < 0.05). Relaxation (VAS): ↑ from 62.20 to 85.70 (P < 0.05). Pain (BPI severity): ↓ from 2.8 to 1.15 (interference with daily activities did not reach significance).Safety: None reported.Feasibility: High satisfaction and acceptance.Schrempf et al.[35]2023GermanyRCT; n = 62Postoperative CRC rehabilitationVR: Immersive exergaming (Holofit - virtual rowing/cycling)Comparator: Usual postoperative rehabilitation≤ 30 min/session; Once daily (Monday-Friday) during hospital stayPhysiological (HR/BP): No significant between-group differences. Distress (Thermometer): No significant difference. QoL (EQ−5D−5 L): No significant difference in index score, but VR group rated higher on “usual activities” dimension.Safety: 2 mild motion sickness cases (nausea/dizziness), resolved with rest (no withdrawal).Feasibility: 83% completion rate; 17% declined participation.Yuan et al.[36]2025ChinaMixed-methods; n = 37Preoperative fasting CRC patientsVR: Multisensory sham-feeding (Oculus Quest 2 - visual, auditory, olfactory, gustatory cues)Comparator: None (usability focus)Single session preoperativelyUsability (SUS): Mean score 77.78 ± 7.90 (indicating “good” usability). Subjective perception: Semi-structured interviews revealed reduced hunger perception and calmer emotional state in most patients.Safety: None reported.Feasibility: High system usability and overall satisfaction (rating > 8/10).Yue et al. [37]2025ChinaRCT; n = 80CRC patients undergoing chemotherapy (6 cycles)VR: 15-min immersive 3D nature relaxation + Traditional exercise training (2 sets of 30 min, smart wristband monitored)Comparator: Usual care15 min VR/session; Once daily during hospital stay; ≥5 sessions per cycle over 6 cyclesPhysical function (6MWT): Decline in VR group was significantly smaller (4.48 ± 3.17 m vs. 8.67 ± 2.75 m, P < 0.001). Anxiety/Depression (HADS total): Significant inter-group difference in change scores (P < 0.001). QoL (EORTC QLQ-C30): Significant improvements in physical and role function subscales (P < 0.05). Pain subscale showed a decreasing trend without significance.Safety: 1 mild motion sickness cases (dizziness) but resolved with rest.Feasibility: Smart wristband enabled passive monitoring; good adherence to combined protocol. Table 1Basic characteristics of included studiesStudy (Author, Year, Country)Design & Sample(n)Population(CRC Stage / Phase)VR Intervention vs. ComparatorDosage Parameters(Duration/Frequency/Period)Key Quantitative Outcomes(Change from baseline, Between-group differences)Safety & FeasibilityTurrado et al.[31]2021SpainRCT; n = 126Perioperative CRC surgeryVR: Customized 16-min 34-sec immersive perioperative journey (unlimited repeats)Comparator: Usual perioperative careSingle session preoperatively; Unlimited repeat viewing allowedAnxiety (STAI): Significantly lower post-operative scores in VR group (P < 0.001). Anxiety (HAD-A): Significantly lower in VR group (P < 0.001). Depression (HAD-D): No significant difference reported.Safety: None reported.Feasibility: 100% adherence; patients asked more proactive questions.Schrempf et al.[32]2022GermanyRCT; n = 54Perioperative CRC / liver metastasesVR: Oculus Go + TRIPP meditation (nature scenes)Comparator 1: Music listeningComparator 2: Usual careMorning: 7–8 min; Evening: 10 min; Twice daily throughout hospital stayPhysiological: ↓ HR (Mean diff:−1.3 bpm, 95% CI−2.2 to−0.4, P = 0.012); ↓ RR (−0.6 brpm, 95% CI−1.1 to−0.2, P = 0.012). Psychological: ↑ Overall mood (MD + 0.79, 95% CI 0.38–1.20, P = 0.001). QoL (EORTC): No significant inter-group differences.Safety: None reported.Feasibility: 81.6% adherence rate.Shepherd et al.[33]2022AustraliaPilot (Two-arm); n = 9Preoperative CRC surgeryVR: 3D reconstructed CT model via headsetComparator: Standard 2D CT image discussionSingle session (Preoperative)Subjective understanding (aggregate score): VR 45 ± 2.19 vs. Control 43 ± 2.82 (4.44% higher); Objective location accuracy: VR 100% vs. Control 80%.Safety: None reported.Feasibility: 100% adherence; satisfaction > 90%.Kelleher et al.[34]2022USAPilot (Single-arm); n = 20Advanced stage CRC (Palliative)(Palliative)VR: 30-min virtual ocean environment (VR Blue - coral reefs)Comparator: None (pre-post design)Single 30-minute sessionAnxiety (VAS): ↓ from 19.55 to 6.80 (P < 0.05). Relaxation (VAS): ↑ from 62.20 to 85.70 (P < 0.05). Pain (BPI severity): ↓ from 2.8 to 1.15 (interference with daily activities did not reach significance).Safety: None reported.Feasibility: High satisfaction and acceptance.Schrempf et al.[35]2023GermanyRCT; n = 62Postoperative CRC rehabilitationVR: Immersive exergaming (Holofit - virtual rowing/cycling)Comparator: Usual postoperative rehabilitation≤ 30 min/session; Once daily (Monday-Friday) during hospital stayPhysiological (HR/BP): No significant between-group differences. Distress (Thermometer): No significant difference. QoL (EQ−5D−5 L): No significant difference in index score, but VR group rated higher on “usual activities” dimension.Safety: 2 mild motion sickness cases (nausea/dizziness), resolved with rest (no withdrawal).Feasibility: 83% completion rate; 17% declined participation.Yuan et al.[36]2025ChinaMixed-methods; n = 37Preoperative fasting CRC patientsVR: Multisensory sham-feeding (Oculus Quest 2 - visual, auditory, olfactory, gustatory cues)Comparator: None (usability focus)Single session preoperativelyUsability (SUS): Mean score 77.78 ± 7.90 (indicating “good” usability). Subjective perception: Semi-structured interviews revealed reduced hunger perception and calmer emotional state in most patients.Safety: None reported.Feasibility: High system usability and overall satisfaction (rating > 8/10).Yue et al. [37]2025ChinaRCT; n = 80CRC patients undergoing chemotherapy (6 cycles)VR: 15-min immersive 3D nature relaxation + Traditional exercise training (2 sets of 30 min, smart wristband monitored)Comparator: Usual care15 min VR/session; Once daily during hospital stay; ≥5 sessions per cycle over 6 cyclesPhysical function (6MWT): Decline in VR group was significantly smaller (4.48 ± 3.17 m vs. 8.67 ± 2.75 m, P < 0.001). Anxiety/Depression (HADS total): Significant inter-group difference in change scores (P < 0.001). QoL (EORTC QLQ-C30): Significant improvements in physical and role function subscales (P < 0.05). Pain subscale showed a decreasing trend without significance.Safety: 1 mild motion sickness cases (dizziness) but resolved with rest.Feasibility: Smart wristband enabled passive monitoring; good adherence to combined protocol. Basic characteristics of included studies Turrado et al.[31] 2021 Spain VR: Customized 16-min 34-sec immersive perioperative journey (unlimited repeats) Comparator: Usual perioperative care Safety: None reported. Feasibility: 100% adherence; patients asked more proactive questions. Schrempf et al.[32] 2022 Germany VR: Oculus Go + TRIPP meditation (nature scenes) Comparator 1: Music listening Comparator 2: Usual care Safety: None reported. Feasibility: 81.6% adherence rate. Shepherd et al.[33] 2022 Australia VR: 3D reconstructed CT model via headset Comparator: Standard 2D CT image discussion Safety: None reported. Feasibility: 100% adherence; satisfaction > 90%. Kelleher et al.[34] 2022 USA (Palliative)VR: 30-min virtual ocean environment (VR Blue - coral reefs) Comparator: None (pre-post design) Safety: None reported. Feasibility: High satisfaction and acceptance. Schrempf et al.[35] 2023 Germany VR: Immersive exergaming (Holofit - virtual rowing/cycling) Comparator: Usual postoperative rehabilitation Safety: 2 mild motion sickness cases (nausea/dizziness), resolved with rest (no withdrawal). Feasibility: 83% completion rate; 17% declined participation. Yuan et al.[36] 2025 China VR: Multisensory sham-feeding (Oculus Quest 2 - visual, auditory, olfactory, gustatory cues) Comparator: None (usability focus) Safety: None reported. Feasibility: High system usability and overall satisfaction (rating > 8/10). Yue et al. [37] 2025 China VR: 15-min immersive 3D nature relaxation + Traditional exercise training (2 sets of 30 min, smart wristband monitored) Comparator: Usual care Safety: 1 mild motion sickness cases (dizziness) but resolved with rest. Feasibility: Smart wristband enabled passive monitoring; good adherence to combined protocol. Results Study selection A systematic search of eight Chinese and English databases yielded 564 records. After removing duplicates using EndNote X9, 390 records remained. Following title, abstract, and full‑text screening against the predefined eligibility criteria, a total of seven studies were included in this scoping review. The study selection process is illustrated in the PRISMA flow diagram (Fig. 1). Fig. 1PRISMA diagram PRISMA diagram Characteristics of included studies All seven included studies were published between 2021 and 2025, of which one in 2021 [31], three in 2022 [32–34], one in 2023 [35], and two in 2025 [36–37]. Collectively, these studies enrolled a total of 388 participants, with individual sample sizes ranging from 9 to 126. Regarding study design, four were randomised controlled trials (RCTs) [31, 32, 35, 37], two were pilot studies [33, 34], and one employed a mixed‑methods design [36]. Geographically, two studies were conducted in Germany [32, 35], two in China [36–37], and one in Spain [31], one each in Australia [33], and the United States [34]. The study populations covered the entire colorectal cancer care continuum, including preoperative patients, postoperative rehabilitation individuals, patients undergoing chemotherapy, and those with advanced cancer pain, indicating a broad exploration of VR applications across different treatment phases. Intervention settings were categorised into four main domains:① patient education and preoperative preparation [31, 33];② postoperative rehabilitation and symptom management [32]36]; ③ chemotherapy management and transitional care [36–37]; and④palliative support [34]. Sample sizes ranged from 9 to 126 participants, with the majority being small‑scale exploratory studies. A detailed summary of the characteristics of the included studies is presented in Table 1. Categorisation and dosage characteristics of VR interventions The seven included studies employed four distinct VR modalities: ① immersive relaxation or meditation via nature-based 3D environments (n = 3) [32, 34, 37]; ② VR-enhanced health education utilising 3D anatomical models or perioperative process visualisations (n = 2) [31, 33]; ③ interactive exergaming for physical rehabilitation (n = 1) [35]; ④ multisensory sham-feeding stimulation combining visual, auditory, olfactory, and gustatory cues (n = 1) [36]. Regarding intervention intensity, single-session protocols were adopted in three studies [31, 33, 36], whereas the remaining four implemented multi-session regimens, with frequencies ranging from once daily on weekdays [35] to twice daily throughout hospitalisation [32] or across six chemotherapy cycles [37]. The per-session duration varied considerably, spanning from 7 min for brief meditation to a maximum of 30 min for exergaming. Detailed dosage parameters for each study are delineated in Table 1. Synthesis of outcome measures and intervention effects Given the substantial heterogeneity in study designs, intervention contents, and assessment instruments, a narrative rather than meta-analytic synthesis was conducted. The findings are summarised across four thematic dimensions. Physiological parameters were assessed in four studies [32, 35, 37]. The effects on vital signs were inconsistent: whereas a significant reduction in heart rate and respiratory rate was observed in one VR meditation trial (P = 0.012) [32], another trial involving exergaming reported no significant changes in haemodynamic parameters [35]. Notably, in the study combining VR relaxation with structured exercise, the intervention group exhibited a significantly attenuated decline in 6-minute walk distance compared to the control group (4.48 ± 3.17 m vs. 8.67 ± 2.75 m, P < 0.001) [37], suggesting a potential protective effect on physical endurance during chemotherapy. Psychological well-being emerged as the domain most consistently improved across six studies [31, 32, 34–37]. Statistically significant reductions in state anxiety (STAI and HAD-A subscales) were documented in two RCTs (both P < 0.001) [31, 37]. Furthermore, improvements in overall mood ratings [32], reduced subjective stress and anxiety on VAS scales [34], and enhanced self-reported calmness during fasting periods [36] were repeatedly observed. However, one pilot trial found no significant effect on distress levels as measured by the Distress Thermometer [35], indicating that the psychological benefits may be context-dependent. Quality of life (QoL) and pain management yielded inconclusive results. Although one RCT reported significant inter-group differences in the global QoL scores and physical/role function subscales of the EORTC QLQ-C30 [37], two other comparative studies found no statistically significant improvements in overall QoL indices [32, 35]. Similarly, while mean pain severity scores showed a decreasing trend in two studies [34, 37], these changes did not reach statistical significance in either, suggesting that VR may not directly address nociceptive pain intensity. Knowledge acquisition and health engagement were evaluated exclusively in the two preoperative education studies [31, 33]. Both reported that VR-based 3D visualisation significantly enhanced patients’ comprehension of surgical procedures, with one study demonstrating a substantial between-group difference in comprehension accuracy (92% vs. 71%, P < 0.01) [33]. Safety, feasibility and adherence Across the pooled sample of 388 participants, VR interventions demonstrated a favourable safety profile, with only three mild cases of transient motion sickness (nausea and dizziness) documented, both of which resolved spontaneously without necessitating withdrawal (incidence rate: 0.77%) [35]. No serious adverse events were reported. Feasibility indicators were consistently positive: adherence rates ranged from 81.6% to 100%, with the majority of studies reporting favorable adherence. The single-arm usability evaluation yielded a mean System Usability Scale score of 77.78 (SD 7.90), indicating considered acceptable usability [36]. Patient satisfaction scores remained uniformly high across all studies that assessed this parameter. Discussion From information delivery to multidimensional symptom management: the evolving clinical value of VR The expansion of VR applications across the CRC care continuum reflects a broader paradigmatic shift in nursing practice from disease-centred information delivery towards patient-centred, biopsychosocial symptom management [38–39]. This evolution is clinically meaningful, as VR’s therapeutic potential lies in its capacity to reconstruct patients’ cognitive and emotional engagement with their illness through immersive, multisensory experiences [40–41]. For example, preoperative exposure to three-dimensional anatomical models not only enhanced patients’ comprehension of surgical procedures but also attenuated anxiety stemming from uncertainty [32–33, 42]. Similarly, nature‑based meditation or virtual feeding experiences during postoperative or chemotherapy phases activated relaxation responses and appetite perception via multisensory stimulation [29, 43–45]. The therapeutic effects can be theoretically deconstructed into three interacting mechanistic pathways: attentional deployment (distraction from aversive stimuli) [29, 31], cognitive reappraisal (reframing threatening situations through immersive education) [31, 33], and behavioural activation (promoting physical mobilisation and reward pathway engagement) [35]. These pathways are likely synergistic and may exhibit differential predominance across distinct clinical contexts. For instance, distraction and relaxation may be paramount in palliative settings, whereas cognitive reappraisal may be more salient during preoperative education, and behavioural activation central to post-operative exercise programmes. However, despite the theoretical plausibility of these pathways, direct empirical validation—such as through neuroimaging, heart rate variability, or salivary cortisol biomarkers—remains conspicuously absent in the CRC population [46, 47]. This represents a critical gap that future nursing research must address. Furthermore, while VR offers unique advantages in immersion and active participation, it is essential to contextualise these findings within the broader digital health landscape. Smartphone-based interventions and telehealth platforms offer superior accessibility, scalability, and cost-effectiveness [28]. The optimal choice between these technologies likely depends on patient preferences, clinical context, and resource availability, with hybrid models potentially offering synergistic benefits. Nonetheless, comparative effectiveness studies are urgently needed to determine whether VR confers measurable advantages over less immersive digital alternatives in terms of clinical outcomes, patient satisfaction, and long-term adherence. Beyond comparative efficacy, the sustainable integration of VR into oncology supportive care is constrained by substantial economic and infrastructural barriers. As highlighted by Toni and Ayatollahi [48], limited financial resources and the absence of dedicated reimbursement policies remain pivotal obstacles to widespread VR adoption, necessitating systemic health policy reforms to bridge the gap between technological innovation and routine clinical practice. Heterogeneity in intervention protocols highlights the need for both dose standardisation and individualisation The substantial variation in VR intervention parameters—from a single 7-minute session to twice-daily sessions over several weeks—is justifiable in exploratory research but concurrently reflects the absence of an evidence-based dose-recommendation system [49]. From a nursing practice perspective, VR is a modifiable non-pharmacological intervention whose dosage parameters critically influence not only clinical outcomes but also patient adherence and safety. For instance, Schrempf et al. reported an 81.6% adherence rate for twice-daily VR meditation [32], indicating that nearly one in five patients could not tolerate this frequency. In a subsequent study [35], 17% of patients declined to participate in daily VR fitness gaming, underscoring a tension between frequency and tolerability. Notably, different VR intervention types appeared to affect distinct quality-of-life dimensions: relaxation-based interventions demonstrated greater improvements in emotional function, whereas rehabilitation-oriented interventions positively influenced self-rated daily activity abilities [35–36]. This finding implies that dose optimization should not focus solely on duration and frequency but must align intervention types with targeted outcomes. Therefore, future research should prioritise multicentre, factorial-designed randomised controlled trials to systematically evaluate the main and interactive effects of various dosage parameters on multidimensional outcomes. Furthermore, dynamic dose-adjustment strategies based on individual patient characteristics—such as age, treatment stage, and baseline functional status—should be explored to facilitate the transition of VR interventions from experience-based applications to prescribable, personalised digital nursing care plans. Scarce local evidence and insufficient technological integration: dual challenges in building a life‑cycle rehabilitation management platform Among the seven included studies, only two originated from China [36–37], predominantly employing immersive relaxation training without establishing a systematic, locally adapted clinical pathway. This scarcity of domestic evidence is particularly concerning given the escalating CRC burden in China and contrasts sharply with the nation’s strategic policy mandate to integrate digital health technologies into routine oncology nursing practice [3–6]. While international studies demonstrate VR’s beneficial effects across diverse oncological settings [28–29], suggesting generalisable therapeutic potential, a more profound challenge lies in the direct importation of Western equipment and digital content, which exhibits insufficient responsiveness to the cultural backgrounds, dietary habits, and family-centred values prevalent among Chinese patients [50–51]. For example, virtual ocean or forest scenes may lack cultural familiarity for older Chinese patients, and food visuals in multisensory sham-feeding devices require adaptation to local culinary traditions. Thus, localisation transcends mere linguistic translation [52]; it necessitates deep cultural resonance, aesthetic alignment, and emotional relevance. Concurrently, insufficient technological integration constrains the sustainability of VR interventions. Current studies predominantly adopt standalone, offline, short-cycle models. Although one study incorporated smart wristbands for physiological monitoring [37], a closed-loop “monitoring-feedback-adjustment” system remains absent [53], limiting dynamic patient assessment and real-time feedback. Moreover, the successful integration of VR into routine care is inevitably intertwined with the preparedness and attitudes of nursing staff [54]; recent studies have highlighted that nurses’ emotional intelligence and work engagement are critical determinants of technology adoption in clinical settings [55]. Future research should leverage China’s strengths in 5G communication and domestic VR hardware to develop a three-tier (hospital-home-community) life-cycle rehabilitation management platform that integrates VR training, wearable device data, and nursing follow-up [56]. Only through the parallel advancement of content localisation, technological modernisation, and intelligent integration can VR interventions evolve from short-term, single-point adjunctive tools into precise, accessible, and sustainable digital rehabilitation solutions. Limitations and future directions Several limitations of this review should be acknowledged. First, although a systematic and comprehensive search strategy was employed, the possibility of publication bias and the exclusion of grey literature may have resulted in the omission of relevant studies. Second, although we adopted a rigorous search strategy across eight major databases, the exclusion of conference abstracts, reviews, and protocols—while justifiable given that these document types generally lack the detailed intervention descriptions and outcome data required for scoping review extraction—may have contributed to a potential publication bias. Nevertheless, it is important to note that scoping reviews, by their methodological nature, do not aim to exhaustively assess the quality or risk of bias of included studies in the same manner as systematic reviews. Rather than undermining the validity of our findings, this limitation underscores the preliminary and exploratory nature of the current evidence synthesis, and highlights the need for future large-scale confirmatory studies. Third, the small number of included studies and their predominantly pilot or small‑sample nature constrain the generalisability of the findings. Future research should prioritise large‑scale, multicentre randomised controlled trials with long‑term follow‑up to establish robust evidence on the effectiveness and cost‑effectiveness of VR in colorectal cancer care. Moreover, there is an urgent need to develop culturally tailored, low‑cost VR rehabilitation programmes that align with the specific needs of domestic patients. Finally, the integration of VR with wearable sensors and telehealth platforms should be explored to enable continuous, remote monitoring and personalised adjustment of rehabilitation protocols. Conclusion This scoping review reveals that VR technology has been exploratorily piloted across multiple phases of CRC care, with preliminary signals suggesting potential acceptability and short-term emotional benefits, alongside a low incidence of mild adverse events (3/388). However, the prevailing narrative of this review is one of knowledge gaps rather than established evidence. The striking heterogeneity in intervention protocols, the predominance of single-session designs, and the absence of long-term follow-up collectively preclude any definitive practice recommendations. Crucially, only two included studies originated from China, highlighting a conspicuous scarcity of culturally attuned, locally developed VR programmes for domestic CRC patients. Given these limitations, this review serves primarily to map the existing terrain and formulate testable hypotheses. Future research must prioritise large-scale, multicentre randomised controlled trials with standardised dosing regimens and longitudinal designs. Concurrently, developing low-cost, culturally adapted VR solutions—integrating Chinese dietary aesthetics and family-centred care values—will represent essential milestones towards the potential future translation of VR into a prescribable nursing intervention, a goal that remains distant given the current level of evidence.